NIH Awards Boston University $57.5 Million for Infectious Diseases Research
The National Institutes of Health (NIH) has awarded $57.5 million to Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL). This five-year grant, provided by the National Institute of Allergy and Infectious Diseases, is intended to support NEIDL's mission to understand and combat major threats to domestic and global health. The funding will directly cover the lab's operations, including biosecurity systems, biosafety programs, facility maintenance, regulatory compliance, specialized biocontainment training, and advanced technical research support services. NEIDL, one of only two national biocontainment labs in the United States, operates at Biosafety Level 4 (BSL-4), enabling researchers to study highly dangerous pathogens such as Ebola, Marburg, Zika, and SARS-CoV-2 in a secure environment. This award follows a previous $7.5 million NIH grant in 2024 for facility modernization.
